To assess the activity of BLUE compounds in the context of autoimmune disease associated with aberrant type I IFN activation, we also measured ISG expression and CXCL10 secretion levels of PBMCs from participants affected by SSc25 (Supplementary Table 2). Here, CXCL10 is linked to autoimmune disease.